Document is current
Any future updates will be listed below
-
Authors
Luo, Qingyu https://orcid.org/0000-0003-4164-637X
Raulston, Evangeline G.
Prado, Miguel A. https://orcid.org/0000-0002-4914-1619
Wu, Xiaowei https://orcid.org/0000-0003-4176-7198
Gritsman, Kira
Whalen, Karley S.
Yan, Kezhi
Booth, Christopher A. G. https://orcid.org/0000-0003-3841-6637
Xu, Ran https://orcid.org/0000-0001-5023-3281
van Galen, Peter https://orcid.org/0000-0002-0735-1570
Doench, John G. https://orcid.org/0000-0002-3707-9889
Shimony, Shai https://orcid.org/0000-0001-7245-9652
Long, Henry W. https://orcid.org/0000-0001-6849-6629
Neuberg, Donna S. https://orcid.org/0000-0003-2566-3145
Paulo, Joao A. https://orcid.org/0000-0002-4291-413X
Lane, Andrew A. https://orcid.org/0000-0001-7380-0226
- License Information
-
More Information
Article History
Received: 2 October 2023
Accepted: 10 April 2024
First Online: 8 May 2024
Competing interests
: K.G. received research funding from iOnctura and ADC Therapeutics. H.W.L. received research funding from Novartis. A.A.L. received research funding from AbbVie and Stemline Therapeutics; consulting fees from Cimeio Therapeutics, IDRx, Jnana Therapeutics, ProteinQure and Qiagen; and has equity as an advisor for Medzown. All other authors declare no competing interests.
